Insertional Mutagenesis Reveals Progression Genes and Checkpoints in MYC/Runx2 Lymphomas
- 1 June 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (11), 5126-5133
- https://doi.org/10.1158/0008-5472.can-07-0433
Abstract
In this study, we have exploited the power of insertional mutagenesis to elucidate tumor progression pathways in mice carrying two oncogenes (MYC/Runx2) that collaborate to drive early lymphoma development. Neonatal infection of these mice with Moloney murine leukemia virus resulted in accelerated tumor onset with associated increases in clonal complexity and lymphoid dissemination. Large-scale analysis of retroviral integration sites in these tumors revealed a profound bias towards a narrow range of target genes, including Jdp2 (Jundm2), D cyclin, and Pim family genes. Remarkably, direct PCR analysis of integration hotspots revealed that every progressing tumor consisted of multiple clones harboring hits at these loci, giving access to large numbers of independent insertion events and uncovering the contrasting mutagenic mechanisms operating at each target gene. Direct PCR analysis showed that high-frequency targeting occurs only in the tumor environment in vivo and is specific for the progression gene set. These results indicate that early lymphomas in MYC/Runx2 mice remain dependent on exogenous growth signals, and that progression can be achieved by constitutive activation of pathways converging on a cell cycle checkpoint that acts as the major rate-limiting step for lymphoma outgrowth. [Cancer Res 2007;67(11):5126–33]Keywords
All Related Versions
This publication has 50 references indexed in Scilit:
- Tumor suppressor gene identification using retroviral insertional mutagenesis in Blm-deficient miceThe EMBO Journal, 2006
- Regulation of histone acetylation and nucleosome assembly by transcription factor JDP2Nature Structural & Molecular Biology, 2006
- The Cyclin-Dependent Kinase (CDK) Family Member PNQALRE/CCRK Supports Cell Proliferation but has no Intrinsic CDK-Activating Kinase (CAK) ActivityCell Cycle, 2006
- The serine/threonine kinase Pim-1The International Journal of Biochemistry & Cell Biology, 2004
- The c-Jun Dimerization Protein 2 Inhibits Cell Transformation and Acts as a Tumor Suppressor GeneJournal of Biological Chemistry, 2004
- Cytochrome P450-based cancer gene therapy: current statusExpert Opinion on Biological Therapy, 2002
- Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damageNature, 2002
- New genes involved in cancer identified by retroviral taggingNature Genetics, 2002
- Mutations in the mitotic check point gene, MAD1L1, in human cancersOncogene, 2001
- The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic miceNature, 1985